FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to genome editing technologies; it can be used in medicine in the treatment of a disease related to tumor antigen expression, and in transplantation. nRNA molecule is proposed that includes tracr and crRNA, where crRNA includes a guiding domain containing any of SEQ ID NO: 1-SEQ ID NO:83 or SEQ ID NO: 5492-SEQ ID NO: 5527.
EFFECT: invention allows for using nRNA for mediating B2M editing in the cell using Cas9, while the cell is not a human germ cell or a human embryo cell.
63 cl, 66 dwg, 43 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| USE OF ANTIBODIES TO SCLEROSTIN FOR TREATING OSTEOGENESIS IMPERFECTA | 2017 |
|
RU2789033C2 |
| MICE CONTAINING MUTATIONS, AS A RESULT OF WHICH FIBRILLIN-1 SHORTENED AT C-TERMINUS IS EXPRESSED | 2017 |
|
RU2721125C1 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
